

**Effects of chronic morphine and morphine withdrawal on gene expression  
in rat peripheral blood mononuclear cells**

*Running title: morphine regulates gene expression in PBMC*

*Stephane Desjardins, Emilie Belkai, Dominique Crete, Laurie Cordonnier, Jean-  
Michel Scherrmann, Florence Noble\*, Cynthia Marie-Claire*

Laboratoire de Neuropsychopharmacologie des addictions (UMR CNRS 7157, INSERM  
U705) Université Paris Descartes, Faculté de Pharmacie, Paris, France

\* Corresponding author

Tel : 33-1-53-73-95-61

Fax : 33-1-53-73-97-19

[florence.noble@univ-paris5.fr](mailto:florence.noble@univ-paris5.fr)

## Summary

Chronic morphine treatment alters gene expression in brain structures. There are increasing evidences showing a correlation, in gene expression modulation, between blood cells and brain in psychological troubles. To test whether gene expression regulation in blood cells could be found in drug addiction, we investigated gene expression profiles in peripheral blood mononuclear (PBMC) cells of saline and morphine-treated rats. In rats chronically treated with morphine, the behavioural signs of spontaneous withdrawal were observed and a withdrawal score was determined. This score enabled to select the time points at which the animals displayed the mildest and strongest withdrawal signs (12h and 36h after the last injection). Oligonucleotide arrays were used to assess differential gene expression in the PBMCs and quantitative real-time RT-PCR to validate the modulation of several candidate genes 12h and 36h after the last injection. Among the 812 differentially expressed candidates, several genes (*Adcy5*, *Htr2a*) and pathways (Map kinases, G-proteins, integrins) have already been described as modulated in the brain of morphine-treated rats. Sixteen out of the twenty four tested candidates were validated at 12h, some of them showed a sustained modulation at 36h while for most of them the modulation evolved as the withdrawal score increased. This study suggests similarities between the gene expression profile in PBMCs and brain of morphine treated rats. Thus, the searching of correlations between the severity of the withdrawal and the PBMCs gene expression pattern by transcriptional analysis of blood cells could be promising for the study of the mechanisms of addiction.

**Keywords:** morphine, dependence, withdrawal, microarray analysis, real-time quantitative RT-PCR

## Introduction

Opiates are among the most largely used addictive drugs. Abused opiates primarily interact with  $\mu$  opioid receptors in the central nervous system and induce long-term behavioral and cellular alterations. A current challenge in opiate addiction is to understand the molecular alterations underlying the adaptative changes observed. The structure of different classes of opioid receptors, the gene encoding opioid receptors, and the signal transduction pathways triggered by opioids have been investigated extensively on neuronal cells in the last fourth decades. Chronic morphine is associated with differential gene expression in several brain structures (Ammon *et al.*, 2003; Beitner-Johnson *et al.*, 1992; Marie-Claire *et al.*, 2004; McClung *et al.*, 2005). Although some of the modifications observed in rodent models of addiction could be found postmortem in the brain of opiate addicts (Ferrer-Alcon *et al.*, 2000, 2004; Albertson *et al.*, 2006), it is difficult to extrapolate all the results obtained from the animal brain to the patients.

Interestingly, in the case of several psychological and neurologic troubles including bipolar disorder, schizophrenia and Parkinson disease, a correlation in gene expression modulation between blood cells and brain has been recently demonstrated (Bowden *et al.*, 2006; Du *et al.*, 2006). These results suggest that studies of the transcription level of certain genes in blood cells may give insights into their modulation in the brain. Moreover, in the case of major depressive disorder studies of gene expression modulations showed that peripheral leucocytes exhibit unique changes in the mRNA levels of several genes that are receptive to antidepressant treatment (Iga *et al.* 2008). Therefore, study of gene expression in peripheral blood mononuclear cells (PBMC) may be useful for a better understanding of brain and neurological disease related pathways, and monitoring of therapeutic responses.

On immune cells, opioid receptors with similar pharmacological and biochemical characteristics to neuronal cells have been reported (Bidlack, 2000; Gaveriaux *et al.*, 1995;

McCarthy et al., 2001; Sharp et al., 1998; Sharp, 2006; Suzuki et al., 2001a; Suzuki et al., 2001b; Suzuki et al., 2000; Wick et al., 1996). Moreover, morphine has been shown to interfere with lymphocytic cells functions following binding to these receptors (Rahim *et al.*, 2002; Roy *et al.*, 2004). Chronic morphine treatment has been shown to alter a number of immune parameters including phagocytosis (Eisenstein and Hilburger, 1998), antibody response in mice (Rahim *et al.*, 2002) and cytokine production in human and mice peripheral blood mononuclear cells (PBMCs) (Pacifici *et al.*, 2000; Peterson *et al.*, 1989). Moreover, morphine withdrawal has been shown to alter immune response in mice (Belcheva *et al.*, 2002; Hilburger *et al.*, 1997). Gaveriaux-Ruff et al showed morphine immunosuppressive effects during an escalating dose protocol in mice and these effects were abolished in mu-receptor knockout animals (Gaveriaux-Ruff *et al.*, 1998).

In order to facilitate the interplay between morphine-treated rat models and opiate-dependent patients we chose to work on an easily accessible tissue: PBMCs. To evaluate whether transcriptional profiling of PBMC could serve to identify genes regulated by morphine rats were chronically treated with morphine during five days, and the behavioral signs of spontaneous withdrawal were observed at different times after the last injection to select the time point at which the animals displayed the minimum withdrawal signs for subsequent analyses. High-density oligonucleotide arrays were used to assess global differential gene expression in the PBMCs. The changes in gene expression were also investigated for several transcripts by quantitative PCR 12h and 36h after the last injection when spontaneous withdrawal signs were minimum and maximum respectively. The regulations of the selected genes were also studied 4h before the last injection in order to estimate the influence of the withdrawal on the observed effects. The results showed that chronic morphine regulates gene expression in PBMCs and interestingly among these genes several have previously been found modulated by morphine treatment in rat brain.

## Materials and Methods

**Animals and drugs:** Male Sprague-Dawley rats (Janvier, Le Genest-Saint-Isle, France) weighing 180-250 g at the beginning of the experiments were housed four per cage. Animals were maintained under standard laboratory conditions ( $21\pm 1^\circ\text{C}$ , 55-60% relative humidity, 12h light/dark cycle, food and water *ad libitum*) for 3 to 5 days before the beginning of the experiments. Care and treatments of animals conformed to the ethical standards and guidelines promulgated by the European Communities Council Directive (86/609/EEC). All efforts were made to minimize animal suffering and to use only the number of animals necessary to produce reliable scientific data. Morphine chlorhydrate (Francopia, France) was dissolved in saline (0.9% NaCl). Morphine and saline solutions (0.1mL per 100 g of body weight) were injected intraperitoneally.

**Animal Treatments:** Dependence was induced in rats by repeated intraperitoneal injections of morphine twice daily at 08.00 AM and 19.00 PM. Morphine doses were progressively increased from 10 to 40 mg kg<sup>-1</sup> injection: first day 2x10 mg kg<sup>-1</sup>, second day 2x20 mg kg<sup>-1</sup>, third day 2x30 mg kg<sup>-1</sup>, fourth and fifth days 2x40 mg kg<sup>-1</sup>. Control group was treated with saline following the same procedure.

**Behavioral studies:** Spontaneous withdrawal syndromes were observed for 15 min in circular plexiglass observation boxes (30 cm wide; 40 cm high) 12h, 18h and 36h after the last morphine injection. Two classes of withdrawal signs were measured: counted signs and observed signs. The number of bouts of teeth chattering, wet dog shakes, mastication and tremor were counted and the sum is a score for each counted signs. Ptosis, defecation, abnormal posture were observed over periods of 3 min, with one point being given for the presence of each sign during each period. The number of periods showing the sign was then

counted (maximum score 5). Global withdrawal score was calculated as the sum of scores for all signs. Body weight was measured during the treatment and before observation period.

**PBMC isolation and RNA extraction:** PBMC isolation was carried out at 3 time-points: 4h before the last injection, 12h and 36h after the last injection on three independent animal groups. Animals were anaesthetized using pentobarbital (100 mg kg<sup>-1</sup>) at the mentioned time points and blood was collected by intracardiac ponction (8-10 mL per animal). Rat PBMCs were isolated from whole blood by density gradient centrifugation on Ficoll-Paque Plus<sup>®</sup> lymphocyte separation medium (GE Healthcare Life Science, France). The layer with PBMCs was removed and washed twice with saline 0.9% and the recovered cells were used directly for total RNA extraction. Total RNA was isolated with Rneasy Micro Kits (Qiagen, Courtaboeuf, France), following the manufacturer's protocol. Each RNA sample was prepared from PBMCs individually isolated from one animal whole blood. Quantification of total RNA was assessed by spectrophotometry using a Nanodrop<sup>®</sup> instrument (Nyxor, France).

**Microarray target preparation and Affymetrix hybridization:**

The quality of the RNA samples was determined by electrophoresis using RNA labs chips (Agilent<sup>®</sup>). Synthesis of cDNA, synthesis and biotinylation of cRNA, fragmentation and hybridization were all performed according to the manufacturer's instructions (Affymetrix, Santa Clara, CA, USA) at the Affymetrix genopole facility (CHU Saint-Louis, Paris). Briefly, double-stranded cDNA was synthesized from total RNA samples using a Superscript Choice Kit with a T7-dt24 primer incorporating a T7 RNA polymerase promoter. Biotinylated cRNA was prepared by in vitro transcription using Enzo Bioarray High Yield RNA Transcript Labeling kit and then fragmented. The fragmented and biotin-labeled cRNA samples were hybridized on Affymetrix<sup>®</sup> Rat Genome RAE230\_2.0 Genechips (containing 31,000 probe sets) according to the manufacturer's instructions. Scanned images of the arrays were converted to numerical data by GCOS software (Affymetrix) and outputted to tab delimited

text files containing Affymetrix<sup>®</sup> ProbeSet ID, signals, present or absent detection calls, and detection *P*-values for each feature on the array. Comparison analyses were conducted using Dchip software 3.1 ([www.dchip.org](http://www.dchip.org)).

### **Microarray analysis:**

DNA-Chip analyzer (DChip) version 2006 (Li and Wong, 2001) was used to analyze Affymetrix data. A comparison between the five hybridizations with morphine treatment and the five controls generated a change of *P*-value. The average percentage of probe sets that were called as present was 60.7% among the different hybridizations except for one of the morphine array (53.5%), this array was then excluded from the subsequent study. Multiple comparisons of four morphine-treated against five control chips were therefore performed. To identify potentially regulated transcripts we chose a cut-off of 50% fold change (treated vs. Control Assay Signal Ratio) and  $p < 0.05$ . Results are displayed as mean of fold induction and/or reduction. The selected transcripts after the Dchip analysis were characterized using NetAffix<sup>™</sup> Analysis center (<https://www.affymetrix.com>) and FatiGO+ (<http://www.fatigo.org>) (Al-Shahrour et al., 2006; Al-Shahrour et al., 2005). We used online tools that are specifically designed to assist investigators to classify the functional roles of the identified differentially expressed genes. The FatiGO+ utilizes the Gene Ontology (GO) database provided by the GO consortium (<http://www.geneontology.org/>) and other databases as KEGG pathway. We compared overexpressed or underexpressed gene lists with rat RAE 230.2 array list. Then a Fisher's exact test was used to check for significant over representation of GO terms in one of the sets. Multiple test correction to account for the multiple hypothesis tested (one for each GO term) was applied (FDR adjusted test).

**Reverse transcription and Real-Time PCR:** Independent batches of RNA were obtained from PBMCs of morphine and saline-treated rats. Total RNAs were reverse transcribed in a final volume of 20  $\mu$ L containing 1X RT-PCR buffer (Invitrogen<sup>®</sup>, France), 500  $\mu$ M each

deoxynucleotide triphosphate, 20 U of RNasin RNase inhibitor (Promega, France), 10 mM DTT, 100 U of Superscript II RNase H<sup>-</sup> reverse transcriptase (Invitrogen, France), 1.5 μM random hexamers (Amersham-Pharmacia<sup>®</sup>, France), and 1 μg of total RNA. Samples were incubated at 20°C for 10 min and 42°C for 30 min, and reverse transcriptase was inactivated by heating at 99°C for 5 min. PCR primers were chosen with the assistance of Oligo 6.42 software (MedProbe, Norway). The primer nucleotide sequences used in this study are listed in Table I. Fluorescent PCR analysis was performed using a LightCycler<sup>®</sup> instrument (Roche Diagnostics, France). The cDNAs were diluted 40-fold and 5 μL were added to the PCR reaction mix to yield a total volume of 10 μL. The PCR reagents were obtained from the FastStart DNA Master SYBR Green I kit (Roche Diagnostics, France). The reaction buffer contained 4 mM MgCl<sub>2</sub> and 0.5 μM of each primer. Amplification protocols consisted of 35-40 cycles of denaturation at 94°C (5 s), annealing at 64°C (5 s), and extension at 72°C (10 s). cDNAs from a naive rat blood were used to generate an external standard curve for each gene. We also quantified transcripts of the gene coding for the Ribosomal Protein Large, P0 (Rplp0), a component of the 60S subunit of ribosomes, as the endogenous RNA control and normalized each sample on the basis of its RPLP0 content.

#### **Statistical analysis:**

All series of data were analyzed with GraphPad Prism<sup>®</sup> 4.0 software. For behavioral experiment, three independent experiments were performed, 15 morphine-treated rats and 15 control rats were compared at each time-point. Data were analyzed by two-way ANOVA with Bonferonni post-test. For body weight study three independent experiments were performed, 28 treated and placebo rats were compared at each time-point. Data were analyzed by two-way repeated measures ANOVA with Bonferonni post-test. For real-time quantitative RT-PCR results, three additional experiments at -4h, +12h and +36h were carried out and the RNAs from 12-14 morphine-treated rats and 10-12 control rats were compared. Data were



analyzed using Student's test between groups at each time point. Differences with  $p < 0.05$  between experimental groups at each point were considered statistically significant.

## Results

**Behavioral experiment:** Physical dependence was induced in male Sprague-Dawley rats by repeated i.p injections of morphine twice daily and the withdrawal signs were monitored in order to determine the time points for the transcriptional studies. The weight gain was monitored every 12h throughout morphine treatment and withdrawal, as shown on figure 1a. A significant increase of 18% was observed in control rats and the weight of rats treated with morphine increased by 13% during the five days of morphine treatment. This difference was not statistically significant. The weight of the control group continued to increase during 4 days after the last injection of saline; while morphine withdrawal induced a significant reduction on weight gain in rats treated with the alkaloid. A maximum difference was observed in body weights of control versus morphine-treated rats 36h after the last injection ( $p<0.001$ ) (Figure 1a).

Morphine-withdrawn animals showed behavioral signs of opiate withdrawal, including wet dog shakes, teeth chattering, diarrhea, mastication, abnormal posture and ptosis. The calculated global withdrawal scores are presented in figure 1b. Withdrawal signs were observed at 12h, 18h and 36h after the last injection and global withdrawal scores of morphine-treated animals were significant ( $p<0.001$ ) at each time-point. Twelve hours after the last morphine injection, all the withdrawal signs were already present but the global withdrawal score was less important than those calculated at 18h and 36h after the last injection. The 12h and 36h time points displaying the minimum and maximum withdrawal scores were therefore selected for the subsequent studies.

**Regulation of gene expression in the PBMCs:** The Affymetrix GeneChip<sup>®</sup> Rat Genome RAE 230 2.0 was used to identify genes differentially regulated in the PBMCs of rats at +12h after the last morphine injection. To obtain a set of differentially expressed genes and global gene expression profiling, we used a combination of  $P$ -value ( $P<0.05$ ) and fold change value

(>1.5 or <0.66). Comparison of chronic morphine with control condition revealed 812 (596 up-regulated and 215 down-regulated) differentially expressed (50% fold or more) gene transcripts in PBMCs of treated rats. Of the 812 significantly modulated candidates, only 394 were annotated and represented 276 distinct genes, whereas the others (51.5 %) were transcribed loci with various levels of matches to known genes. A selective list of the genes modulated in this study is presented in Table II. We used NetAffix™ Analysis Center and FatiGO+ to identify the signalling pathways and genes families regulated by chronic morphine (Figure 2). The results revealed several genes families that have been previously described as modulated by chronic morphine in the brain. We found that 7% of the 276 annotated genes regulated belong to the G-protein coupled receptor protein signalling pathway, these include G-protein coupled receptors and G-protein coupled protein. Signal transduction pathways were also represented such as mitogen activated protein kinase pathway and cAMP pathway. Other regulated genes have a role in immunity and defense process interleukin 1 receptor, type I (Il1r1), interferon beta 1 (Ifnb1), and a role in pro-apoptotic Tissue inhibitor of metalloproteinase 3 (Timp3), Bcl2 modifying factor (Bmf), guanine nucleotide binding protein, alpha q (Gnaq), NCK-associated protein 1 (Nckap1), and anti-apoptotic pathways [Sphingosine kinase 1 (Sphk1), Chemokine (C-C motif) ligand 2 (Ccl2), Fibroblast growth factor 8 (Fgf8)]. Three 5-hydroxytryptamine receptors 6, 7 and 2a (Htr6, Htr7 and Htr2a), and calcium channels were also identified.

#### **Validation of differentially regulated genes by quantitative RT-PCR at 12h:**

In order to validate the regulation of 24 selected genes we performed quantitative real-time RT-PCR on samples collected at the same time-point (12h) as for the array analysis (minimum withdrawal). We chose genes of the G protein pathway (Gprk5, Gng11), genes of the Mapk pathway (similar to mitogen-activated protein kinase kinase kinase 5 isoform

2), mitogen-activated protein kinase 7 (Mapk7) and genes known to be modulated in the brain by morphine treatment (Adcy5, Adenosine kinase, Htr2a). Since morphine promotes cells apoptosis, we also chose to confirm the regulation of genes implicated in this process such as Bmf, Nckap1, Timp3, and also genes implicated in cell adhesion such as Integrin beta 1 (Itgb1) and integrin alpha 6 (Itga6). Out of the 18 tested genes 12 were validated by Q-RT-PCR (Table III). Furthermore, the fold-changes obtained were similar to those calculated in the array experiments (Table II and table III). We also tested 6 genes that belong to the tested families and almost fulfill the criteria detailed in the material and methods section: regulator of G-protein signalling 10 (Rgs10) (1.46), membrane interacting protein of Rgs16 (Mir16) (1.39), mitogen-activated protein kinase 8 interacting protein 3 (Mapk8ip3) (1,35), adaptor-related protein complex 1, sigma 1 subunit (Ap1s1) (1.36), calpain 2 (Capn2) (1.4), RAS, guanyl releasing protein 2 (Rasgrp2) (1.22). We found that the regulations of Rgs10, Mir16, Capn2, Rasgrp2, were verified by quantitative real-time RT-PCR at 12h (Table III).

### **Regulation of differentially regulated genes by quantitative RT-PCR at 36h.**

In order to compare the expression levels at the minimum and maximum withdrawal scores in our model, we carried out an additional independent experiment at 36h to analyze the differential expression levels between morphine-treated and control rats of 18 genes confirmed or not at 12h. Four groups of genes could be distinguished according to their pattern of regulation at +12h and +36h. Four genes (Adcy5, Mir16, Camk4, and Anxa3) were significantly up-regulated at 12h but significantly down-regulated at 36h. A group with Itga6 and Rasgrp2 showed a sustained up-regulation at 12h and 36h. A group with Adk, Nckap1, Gng11, Gprk5, Rgs10, Capn2, Fgl2, Sod2, Timp3, Ap1s1, and Itgb1 showed a significant up-regulation at 12h but no modulation at 36h. And a fourth group composed of Mapk8ip3 and Htr2A was not significantly modulated at 12h but significantly regulated at 36h.

### **Regulation of the validated genes during chronic morphine treatment.**

In order to know how the validated genes were being expressed before the onset of the withdrawal process, quantitative real time PCR was performed on PBMCs of rat sacrificed on day 5. For all the tested genes the regulations observed 4h before the last morphine injection confirmed those obtained 12 hours after the last morphine injection (Table III). Furthermore, the fold changes observed at -4h were very similar to those obtained at +12h. In addition no significant regulation was found at -4h for the 7 genes that were not modulated at +12H.

## Discussion

The aim of this study was to identify differentially expressed genes in blood cells of morphine-dependent rats in spontaneous withdrawal situation. The large majority of studies carried out to date have used opioid receptor antagonist-precipitated withdrawal syndrome. However, this experimental approach greatly differs from the clinical setting where the opiate withdrawal syndrome occurs as a result of drug intake cessation. To better mimic these conditions, spontaneous withdrawal was evaluated. We observed classical signs used in behavioral studies and found low levels of withdrawal scores. Indeed spontaneous withdrawal induces milder behavioral modulation than the naloxone-precipitated one. As expected, the severity of opiate withdrawal varied as a function of the time interval between the last morphine administration and testing. In order to study the modifications in gene expressions in morphine-dependent rats and to minimize the transcriptional effects of withdrawal, the +12h time point was selected for microarray analysis. At this time point, withdrawal symptoms and loss of weight were at their minimum. At 36h, the withdrawal signs were maximum, and this time point was therefore selected for comparison with the 12h results. An additional time point (4h before the last injection) was chosen in order to assess the modulation of the selected candidate genes before the beginning of the withdrawal process.

Several studies have demonstrated characteristic blood genomic profiles for different brain disorders and neurologic diseases (Du *et al.*, 2006; Tang *et al.*, 2005; Tang *et al.*, 2004). A study of gene expression in PBMCs from schizophrenic patients suggested a correlation between the gene expression modulations patterns in PBMCs and the severity of the schizophrenic syndrome (Bowden *et al.*, 2006). In the case of migraine suffering patients differential gene expression modulations were found in platelets as compared to control patients (Hershey *et al.*, 2004). Tang and coworkers also found a specific gene expression pattern in PBMCs from Tourette syndrome patients (Tang *et al.*, 2005). Moreover in the case

of depression the low level of expression of alpha2a adrenergic receptors observed in the platelets of depressive patients could be increase after a treatment with an antidepressive compound (Garcia-Sevilla *et al.*, 2004). These results suggest a correlation between the gene expression regulations in the brain and the blood cells in these pathologies. The identification of an easily accessible tissue (blood) where modifications of gene expression following chronic morphine treatment could give insight to those occurring in the CNS would facilitate clinical research on the mechanisms of addiction in humans (Sullivan *et al.*, 2006). In this study, we used PBMCs as a model to study blood expression profile following morphine treatment.

Our results describe the regulation of various genes and pathways in PBMCs of rats treated with morphine. 17 out the 24 tested genes were validated by quantitative real-time PCR at +12h. Interestingly the modulations observed on the last day of the morphine treatment were similar to those obtained at the +12h time point of the spontaneous withdrawal but evolved as the withdrawal state worsens. Among the regulated pathways in PBMCs some have been previously identified in vitro in transcription studies. Stefano et al have showed a regulation of apoptosis and cell adhesion genes in human peripheral blood leukocytes after acute morphine treatment (Stefano *et al.*, 2005). In addition morphine has been shown to modulate immune responses (Eisenstein and Hilburger, 1998).

Interestingly, among the genes found regulated in PBMCs several have been previously reported to be involved in responses to morphine in different brain regions. The two major transcription pathways (Mapk and G protein coupled receptor) reported to be regulated by morphine treatment in brain (Asensio *et al.*, 2006; Fan *et al.*, 2002; Traynor and Neubig, 2005) were also found regulated in PBMCs. Opioid receptor activations lead to physiological responses via coupling to inhibitory guanine nucleotide-binding regulatory protein (Gold *et al.*, 2003), modulating several effectors, such as adenylyl cyclases, and voltage-gated Ca<sup>2+</sup>

channels. In the present study, modulations of genes belonging to two major components of the development of opiate addiction were found in the PBMCs: the G-protein coupled receptor signalling (Gprk5, gng11, Rgs 10, Mir16) and the cAMP signalling (Adcy5) pathways. Adcy5 has been shown to play an important role for the development of morphine behavioral effects (Kim *et al.*, 2006). Nestler et al have shown that decreased activation of ERK1/2 might be relevant in modulating long lasting forms of synaptic plasticity in opiate addiction (Nestler, 2001). In the present study we observed an increase in the expression of several mitogen-activated protein kinases (Mapk7, similar to Mapkkkk5). Mapk pathway has been shown to be activated in various regions of rat brain by opioid receptors coupled to G-proteins (Schulz *et al.*, 2004).

Electrophysiological studies have suggested a functional relationship between the opioid and serotonergic systems in the rat prefrontal cortex involving the  $\mu$  and Htr2a receptors (Marek, 2003). Moreover, an implication of Htr2a receptors in the dopamine release, locomotor response and behavioural sensitization to morphine has been demonstrated (Auclair *et al.*, 2004). The present results showing a regulation of the serotonin receptor Htr2a by morphine treatment are consistent with these findings. Integrins are transmembrane receptors allowing the interactions of cells with the extracellular matrix (Uings and Farrow, 2000). They are involved in several cellular functions including the modulation of G-protein-coupled receptors signalling (Berg *et al.*, 2007). In this study we found that morphine treatment upregulated two integrins genes (Itgb1 and Itga6) in rat PBMCs. Moreover, the severity of the withdrawal symptoms did not affect the expression of these two genes. Interestingly, Itgb1 has been recently shown to regulate opioid receptor signalling in sensory neurons (Berg *et al.*, 2007).

In conclusion, our data show that chronic morphine treatment induces transcriptional modifications in PBMCs that evolve with the withdrawal state of the animals. This suggests



that PBMC gene expression patterns could be indicative of the disease stage. For some of the modulated genes the PBMC regulations confirmed previously reported brain modulations. In order to better characterize the correlations suggested here, a study of the modulation of the differentially regulated genes obtained in PBMCs, in brain structures involved in addiction, is currently carried out. This approach could help to identify important diagnostic/prognostic markers as well as potential therapeutic targets and mechanistic pathways.

## **ACKNOWLEDGMENTS**

This work was supported by the Consortium national de recherche en génomique (CNRG) and the Mission Interministerielle de Lutte contre la Drogue et la Toxicomanie (MILDT).

### List of references

- Al-Shahrour, F., Minguéz, P., Tarraga, J., Montaner, D., Alloza, E., Vaquerizas, J. M., Conde, L., Blaschke, C., Vera, J., Dopazo, J., 2006. Babelomics: a systems biology perspective in the functional annotation of genome-scale experiments. *Nucleic Acids Res* 34, W472-476.
- Al-Shahrour, F., Minguéz, P., Vaquerizas, J. M., Conde, L., Dopazo, J., 2005. BABELOMICS: a suite of web tools for functional annotation and analysis of groups of genes in high-throughput experiments. *Nucleic Acids Res* 33, W460-464.
- Albertson, D. N., Schmidt, C. J., Kapatos, G., Bannon, M. J., 2006. Distinctive profiles of gene expression in the human nucleus accumbens associated with cocaine and heroin abuse. *Neuropsychopharmacology* 31, 2304-2312.
- Ammon, S., Mayer, P., Riechert, U., Tischmeyer, H., Holtt, V., 2003. Microarray analysis of genes expressed in the frontal cortex of rats chronically treated with morphine and after naloxone precipitated withdrawal. *Brain Res Mol Brain Res* 112, 113-125.
- Asensio, V. J., Miralles, A., Garcia-Sevilla, J. A., 2006. Stimulation of mitogen-activated protein kinase kinases (MEK1/2) by mu-, delta- and kappa-opioid receptor agonists in the rat brain: regulation by chronic morphine and opioid withdrawal. *Eur J Pharmacol* 539, 49-56.
- Auclair, A., Drouin, C., Cotecchia, S., Glowinski, J., Tassin, J. P., 2004. 5-HT<sub>2A</sub> and alpha<sub>1b</sub>-adrenergic receptors entirely mediate dopamine release, locomotor response and behavioural sensitization to opiates and psychostimulants. *Eur J Neurosci* 20, 3073-3084.
- Beitner-Johnson, D., Guitart, X., Nestler, E. J., 1992. Neurofilament proteins and the mesolimbic dopamine system: common regulation by chronic morphine and chronic cocaine in the rat ventral tegmental area. *J Neurosci* 12, 2165-2176.

- Belcheva, M. M., Haas, P. D., Tan, Y., Heaton, V. M., Coscia, C. J., 2002. The fibroblast growth factor receptor is at the site of convergence between mu-opioid receptor and growth factor signaling pathways in rat C6 glioma cells. *J Pharmacol Exp Ther* 303, 909-918.
- Berg, K. A., Zardeneta, G., Hargreaves, K. M., Clarke, W. P., Milam, S. B., 2007. Integrins regulate opioid receptor signaling in trigeminal ganglion neurons. *Neuroscience* 144, 889-897.
- Bidlack, J. M., 2000. Detection and function of opioid receptors on cells from the immune system. *Clin Diagn Lab Immunol* 7, 719-723.
- Bowden, N. A., Weidenhofer, J., Scott, R. J., Schall, U., Todd, J., Michie, P. T., Tooney, P. A., 2006. Preliminary investigation of gene expression profiles in peripheral blood lymphocytes in schizophrenia. *Schizophr Res* 82, 175-183.
- Du, X., Tang, Y., Xu, H., Lit, L., Walker, W., Ashwood, P., Gregg, J. P., Sharp, F. R., 2006. Genomic profiles for human peripheral blood T cells, B cells, natural killer cells, monocytes, and polymorphonuclear cells: comparisons to ischemic stroke, migraine, and Tourette syndrome. *Genomics* 87, 693-703.
- Eisenstein, T. K., Hilburger, M. E., 1998. Opioid modulation of immune responses: effects on phagocyte and lymphoid cell populations. *J Neuroimmunol* 83, 36-44.
- Fan, X., Zhang, J., Zhang, X., Yue, W., Ma, L., 2002. Acute and chronic morphine treatments and morphine withdrawal differentially regulate GRK2 and GRK5 gene expression in rat brain. *Neuropharmacology* 43, 809-816.
- Ferrer-Alcon, M., Garcia-Sevilla, J. A., Jaquet, P. E., La Harpe, R., Riederer, B. M., Walzer, C., Guimon, J., 2000. Regulation of nonphosphorylated and phosphorylated forms of neurofilament proteins in the prefrontal cortex of human opioid addicts. *J Neurosci Res* 61, 338-349.

- Ferrer-Alcon, M., La Harpe, R., Garcia-Sevilla, J. A., 2004. Decreased immunodensities of [mu]-opioid receptors, receptor kinases GRK 2/6 and [beta]-arrestin-2 in postmortem brains of opiate addicts. *Molecular Brain Research* 121, 114-122.
- Garcia-Sevilla, J. A., Ventayol, P., Perez, V., Rubovszky, G., Puigdemont, D., Ferrer-Alcon, M., Andreoli, A., Guimon, J., Alvarez, E., 2004. Regulation of platelet alpha 2A-adrenoceptors, Gi proteins and receptor kinases in major depression: effects of mirtazapine treatment. *Neuropsychopharmacology* 29, 580-588.
- Gaveriaux-Ruff, C., Matthes, H. W., Peluso, J., Kieffer, B. L., 1998. Abolition of morphine-immunosuppression in mice lacking the mu-opioid receptor gene. *Proc Natl Acad Sci U S A* 95, 6326-6330.
- Gaveriaux, C., Peluso, J., Simonin, F., Laforet, J., Kieffer, B., 1995. Identification of kappa- and delta-opioid receptor transcripts in immune cells. *FEBS Lett* 369, 272-276.
- Gold, S. J., Han, M. H., Herman, A. E., Ni, Y. G., Pudiak, C. M., Aghajanian, G. K., Liu, R. J., Potts, B. W., Mumby, S. M., Nestler, E. J., 2003. Regulation of RGS proteins by chronic morphine in rat locus coeruleus. *Eur J Neurosci* 17, 971-980.
- Hershey, A. D., Tang, Y., Powers, S. W., Kabbouche, M. A., Gilbert, D. L., Glauser, T. A., Sharp, F. R., 2004. Genomic abnormalities in patients with migraine and chronic migraine: preliminary blood gene expression suggests platelet abnormalities. *Headache* 44, 994-1004.
- Hilburger, M. E., Adler, M. W., Rogers, T. J., Eisenstein, T. K., 1997. Morphine alters macrophage and lymphocyte populations in the spleen and peritoneal cavity. *J Neuroimmunol* 80, 106-114.
- Kim, K. S., Lee, K. W., Lee, K. W., Im, J. Y., Yoo, J. Y., Kim, S. W., Lee, J. K., Nestler, E. J., Han, P. L., 2006. Adenylyl cyclase type 5 (AC5) is an essential mediator of morphine action. *Proc Natl Acad Sci U S A* 103, 3908-3913.

- Li, C., Wong, W. H., 2001. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. *Proc Natl Acad Sci U S A* 98, 31-36.
- Marek, G. J., 2003. Behavioral evidence for mu-opioid and 5-HT<sub>2A</sub> receptor interactions. *Eur J Pharmacol* 474, 77-83.
- Marie-Claire, C., Courtin, C., Roques, B. P., Noble, F., 2004. Cytoskeletal genes regulation by chronic morphine treatment in rat striatum. *Neuropsychopharmacology* 29, 2208-2215.
- McCarthy, L., Wetzel, M., Sliker, J. K., Eisenstein, T. K., Rogers, T. J., 2001. Opioids, opioid receptors, and the immune response. *Drug Alcohol Depend* 62, 111-123.
- McClung, C. A., Nestler, E. J., Zachariou, V., 2005. Regulation of gene expression by chronic morphine and morphine withdrawal in the locus ceruleus and ventral tegmental area. *J Neurosci* 25, 6005-6015.
- Nestler, E. J., 2001. Molecular basis of long-term plasticity underlying addiction. *Nat Rev Neurosci* 2, 119-128.
- Pacifici, R., di Carlo, S., Bacosi, A., Pichini, S., Zuccaro, P., 2000. Pharmacokinetics and cytokine production in heroin and morphine-treated mice. *Int J Immunopharmacol* 22, 603-614.
- Peterson, P. K., Gekker, G., Brummitt, C., Pentel, P., Bullock, M., Simpson, M., Hitt, J., Sharp, B., 1989. Suppression of human peripheral blood mononuclear cell function by methadone and morphine. *J Infect Dis* 159, 480-487.
- Rahim, R. T., Adler, M. W., Meissler, J. J., Jr., Cowan, A., Rogers, T. J., Geller, E. B., Eisenstein, T. K., 2002. Abrupt or precipitated withdrawal from morphine induces immunosuppression. *J Neuroimmunol* 127, 88-95.
- Roy, S., Wang, J., Gupta, S., Charboneau, R., Loh, H. H., Barke, R. A., 2004. Chronic morphine treatment differentiates T helper cells to Th2 effector cells by modulating transcription factors GATA 3 and T-bet. *Journal of Neuroimmunology* 147, 78-81.

- Schulz, R., Eisinger, D. A., Wehmeyer, A., 2004. Opioid control of MAP kinase cascade. *European Journal of Pharmacology* 500, 487-497.
- Sharp, B. M., 2006. Multiple opioid receptors on immune cells modulate intracellular signaling. *Brain Behav Immun* 20, 9-14.
- Sharp, B. M., Roy, S., Bidlack, J. M., 1998. Evidence for opioid receptors on cells involved in host defense and the immune system. *J Neuroimmunol* 83, 45-56.
- Stefano, G. B., Burrill, J. D., Labur, S., Blake, J., Cadet, P., 2005. Regulation of various genes in human leukocytes acutely exposed to morphine: expression microarray analysis. *Med Sci Monit* 11, MS35-42.
- Sullivan, P. F., Fan, C., Perou, C. M., 2006. Evaluating the comparability of gene expression in blood and brain. *Am J Med Genet B Neuropsychiatr Genet* 141, 261-268.
- Suzuki, S., Chuang, L. F., Doi, R. H., Bidlack, J. M., Chuang, R. Y., 2001a. Kappa-opioid receptors on lymphocytes of a human lymphocytic cell line: morphine-induced up-regulation as evidenced by competitive RT-PCR and indirect immunofluorescence. *Int Immunopharmacology* 1, 1733-1742.
- Suzuki, S., Chuang, T. K., Chuang, L. F., Doi, R. H., Chuang, R. Y., 2001b. Morphine upregulates kappa-opioid receptors of human lymphocytes. *Adv Exp Med Biol* 493, 81-87.
- Suzuki, S., Miyagi, T., Chuang, T. K., Chuang, L. F., Doi, R. H., Chuang, R. Y., 2000. Morphine upregulates mu opioid receptors of human and monkey lymphocytes. *Biochem Biophys Res Commun* 279, 621-628.
- Tang, Y., Gilbert, D. L., Glauser, T. A., Hershey, A. D., Sharp, F. R., 2005. Blood gene expression profiling of neurologic diseases: a pilot microarray study. *Arch Neurol* 62, 210-215.
- Tang, Y., Schapiro, M. B., Franz, D. N., Patterson, B. J., Hickey, F. J., Schorry, E. K., Hopkin, R. J., Wylie, M., Narayan, T., Glauser, T. A., Gilbert, D. L., Hershey, A. D., Sharp, F. R., 2004.

Blood expression profiles for tuberous sclerosis complex 2, neurofibromatosis type 1, and Down's syndrome. *Ann Neurol* 56, 808-814.

Traynor, J. R., Neubig, R. R., 2005. Regulators of G protein signaling and drugs of abuse. *Mol Interv* 5, 30-41.

Uings, I. J., Farrow S. N. 2000. Cell receptors and cell signalling. *J. Clin. Pathol.* 53, 295-299

Wick, M. J., Minnerath, S. R., Roy, S., Ramakrishnan, S., Loh, H. H., 1996. Differential expression of opioid receptor genes in human lymphoid cell lines and peripheral blood lymphocytes. *J Neuroimmunol* 64, 29-36.



## Figures legends

**Figure 1:** a) Evolution of weight variation as compared to weight before the first injection, n=15 rats per treatment. Body weight of each rat was measured before the injection (twice daily from 5 days) or the observation (from +12h to 96h after the last injection). Three independent experiments were achieved. Results are expressed as mean  $\pm$  SEM. \* p<0.05, \*\*p<0.01, \*\*\* p < 0.001, NS: non significant Two-way repeated measure ANOVA. b) Evolution of global withdrawal score. Mean  $\pm$  SEM of opiate withdrawal score ( n= 15 rats per treatment) at +12h, +18h and +36h after the last injection. Two Way ANOVA \* p<0.05; \*\* p<0.01; \*\*\* p<0.001.


**Figure 2:** 812 gene transcripts were identified, 596 up-regulated and 215 down-regulated genes under morphine treatment. Only 276 were identified as distinct gene. Data were presented according to Gene ontology classification of the biological processes most frequently involved by the 276 genes. The percentage distribution of up- and down-regulated genes with GO annotation in each category of biological process was shown. Each asterisk (\*) represent a significant differential regulation in the category compared (p<0.05 by Fisher).

**Table I:** Primer sequences used for SYBR Green-based real-time quantitative polymerase chain reaction.


| Gene                          | gene forward primer (sense)   | gene reverse primer (antisense)   |
|-------------------------------|-------------------------------|-----------------------------------|
| Adcy5                         | 5' ATGGGTCTGCTTTTCCACT 3'     | 5' GGAGGTGTGAGGAGAGAATG 3'        |
| Adk                           | 5' TGAGCGTTCCTGCCTTGA 3'      | 5' CCCTCTACGGTAATAATG 3'          |
| Anxa3                         | 5' CTGTGGAGGAGATGATTGAAGA 3'  | 5' TCGTACAGCACTCCAGCA 3'          |
| Ap1s1                         | 5' CTCCAGCCCTACATACAAAC 3'    | 5' CCCTAAAGCCTTCAGTGG 3'          |
| Bmf                           | 5' GAGCCAAGTAGTCAGTTACCAC 3'  | 5' GTCCAATCCAGTCCAGTCAT 3'        |
| Camk4                         | 5' CATCCTACACCCTCCACAAGTCT 3' | 5' ACAAGGCTGGTCCCCCTC 3'          |
| Capn2                         | 5' CAGCAAGCCCTCTTAGACT 3'     | 5' TCTGAGCCCTGTTCTCC 3'           |
| Fgl2                          | 5' TATCGCTTTTTGGCTGAACA 3'    | 5' AGAGGCTGAAGACATTGCT 3'         |
| Gng 11                        | 5' TCCAGAAGACAAGAATCCC 3'     | 5' ATTTCCCTCCAGAGTTCCT 3'         |
| Gprk5                         | 5' ACTTGAAGCAGAATTGTAAC 3'    | 5' TGGGGGAACAGTATCCTATC 3'        |
| Htr2a                         | 5' CAGGCGAGTCACAGGATAG 3'     | 5' CACAGCAGTAAAAGACAGCA 3'        |
| Itga6                         | 5' GAAGTGAGGACCCTTGCTGATG 3'  | 5' CGAACCTGTGCCTTAGTGACAA 3'      |
| Itgb1                         | 5' AAAGCAAATGCCAAATCTGTG 3'   | 5' TTCCTTCTGTAAAAATGTCGTA 3'      |
| Mapk7                         | 5' CCCGCTGACATTGAGTCT 3'      | 5' GTGGGTCTCAGGGTCTTG 3'          |
| Mapk8ip3                      | 5' TGGAGAGCAACTGACAAGA 3'     | 5' AGTGCCCCTGAAGAGTAAG 3'         |
| Mir16                         | 5' AAAGGAATCCAGGTTGTTAGTT 3'  | 5' CAAGGTGGGACTCGTAGTAAT 3'       |
| Nckap1                        | 5' GGAAGCAGACTCAGTTTCTC 3'    | 5' CAGCAGGGTCCAAGGTAG 3'          |
| Ptpn22_predicted              | 5' CAAGCAAGCCTACAGAATG 3'     | 5' TGGTCCTTTGGGTTTTG 3'           |
| Ralgps2                       | 5' GAAGGCAAAAACCCACAGT 3'     | 5' CCACCACAGACACATTCTTA 3'        |
| Rasgrp2 predicted             | 5' GAAGCCTTTGATGACTCTGG 3'    | 5' GGGATTGCTGATAGAAGTGG 3'        |
| similar to Mapkkkk5 isoform 2 | 5' CTCACAGCAATCTCTACATCC 3'   | 5' CATTGCTGCTTGTCACT 3'           |
| Rgs10                         | 5' GGCGGACTGAGGAAGAG 3'       | 5' CACAACAAGCAATGACATC 3'         |
| RPLP0                         | 5' GGGGCCACCTGGAGAACAAC 3'    | 5' GCA GCA GCT GGC ACC TTA TTG 3' |
| SOD2                          | 5' GGCTTGGCTTCAATAAGGAG 3'    | 5' ATCCCAGCAGTGGGAATA 3'          |
| Timp3                         | 5' GAAGCCTCTGAAAGTCTCTG 3'    | 5' CCCACCTCTCCACAAAGT 3'          |

Figure 1

a



b




**Table II:** Affymetrix data at 12h of selective genes. Fold changes compare PBMC's treated rats to PBMC's saline rats. In bracket, fold change of different probe sets on the array

| Accession   | Full name of gene   | gene                    | Fold change | Accession                                   | Full name of gene   | gene            | Fold change |
|---|---|-------------------------|-------------|---|---|-----------------|-------------|
| <b>Signal transduction</b>                                  |   |                         |             | <b>Integrin-mediated signalling pathway</b> |   |                 |             |
| NM_022600   | Adenylate cyclase 5   | Adcy5                   | 2.69        | AI137931                                    | Integrin, alpha 6   | Itga6           | 1.89        |
| NM_012823   | Annexin A3  | Anxa3                   | 0.34        | BF418243                                    | Integrin alpha V (predicted)                                  | Itgav predicted | 1.65        |
| M63334  | Calcium/calmodulin-dependent protein kinase IV  | Camk4                   | 2.69        | NM_017022                                   | Integrin beta 1 (fibronectin receptor beta)                   | Itgb1           | 1.83        |
| AJ005424  | Mitogen-activated protein kinase 7  | Mapk7                   | 0.66        | NM_012587                                   | Integrin binding sialoprotein                                 | lbsp            | 2.3         |
| BM387133  | Ral GEF with PH domain and SH3 binding motif 2  | Ralgps2                 | 0.64        | <b>Metabolism</b>                           |   |                 |             |
| AI102560  | Rap guanine nucleotide exchange factor (GEF) 5  | Rapgef5                 | 0.49        | NM_012786                                   | Cytochrom c oxidase subunit VIII-H (heart/muscle)             | Cox8h           | 0.47        |
| BI279720  | RAS-like, family 12 (predicted)   | Rasl12 predicted        | 0.64        | M58041                                      | Cytochrome P450, family 2, subfamily c, polypeptide 70        | Cyp2c70         | 0.33        |
| AI577569  | RAS protein-specific guanine nucleotide-releasing factor 1                            | Rasgrf1                 | 3.97        | NM_031509                                   | Glutathione S-transferase A3                                  | Gsta3           | 2.57        |
| AA945062  | Rho GTPase activating protein 8   | Arhgap8                 | 0.38        | NM_012796                                   | Glutathione S-transferase, theta 2                            | Gstt2           | 1.61        |
| BF396580  | Rho GTPase activating protein 5   | Arhgap5                 | 0.39        | U48220                                      | Cytochrome P450, family 2, subfamily d, polypeptide 22        | Cyp2d22         | 1.88        |
| BI291366  | similar to mitogen-activated protein kinase kinase kinase 5 isoform 2 (predicted)     | Similar Mapk5 isoform 2 | 2.23        | <b>Cell differentiation</b>                 |   |                 |             |
| <b>G-protein coupled receptor protein signaling pathway</b> |   |                         |             | NM_019242                                   | Interferon-related developmental regulator 1                  | lfrd1           | 1.55        |
| NM_017254   | 5-hydroxytryptamine (serotonin) receptor 2A   | Htr2a                   | 1.74        | NM_012731                                   | Neurotrophic tyrosine kinase, receptor, type 2                | Ntrk2           | 1.62        |
| L03202  | 5-hydroxytryptamine (serotonin) receptor 6  | Htr6                    | 0.64        | AB049572                                    | sphingosine kinase 1  | Sphk1           | 1.73        |
| X69663  | 5-hydroxytryptamine (serotonin) receptor 7  | Htr7                    | 1.67        | <b>Inflammatory</b>                         |   |                 |             |
| BG379920  | Adenosine A3 receptor   | Eaf2/Adora3             | 1.6         | NM_013123                                   | Interleukin 1 receptor, type I                                | Il1r1           | 1.78        |
| NM_012768   | Dopamine receptor D5  | Drd5                    | 1.8         | <b>Transcription</b>                        |   |                 |             |
| AI012890  | G protein-coupled receptor 43   | Gpr43                   | 2.5         | BE096021                                    | Jun D proto-oncogene  | Jund            | 4.5         |
| BF404188  | G protein-coupled receptor 137B (predicted)   | Gpr137b                 | 2.01        | BG666291                                    | Kruppel-like factor 7 (ubiquitous) (predicted)                | Klf7 predicted  | 2.2         |
| NM_030829   | G protein-coupled receptor kinase 5   | Gprk5                   | 2.08        | <b>Immune response</b>                      |   |                 |             |
| NM_022396   | Guanine nucleotide binding protein (G protein), gamma 11                              | Gng11                   | 1.57        | BF403233                                    | RT1 class Ib, locus M3  | RT1-M3          | 2.31        |
| NM_031034   | Guanine nucleotide binding protein, alpha 12  | Gna12                   | 1.67        | BI292055                                    | RT1 class Ib, locus Aw2                                       | RT1-Aw2         | 0.45        |
| BE117491  | Guanine nucleotide binding protein, alpha q polypeptide                               | Gnaq                    | 1.54        | NM_031530                                   | chemokine (C-C motif) ligand 2                                | Ccl2            | 0.18        |
| BI293698  | HtrA serine peptidase 3 (predicted)   | Htra3 predicted         | 0.56        | <b>Others functions</b>                     |   |                 |             |
| NM_022800   | purinergic receptor P2Y, G-protein coupled 12   | P2ry12                  | 2.77        | BI298352                                    | Adaptor-related protein complex 3, beta 2 subunit (predicted) | Ap3b2 predicted | 2.83        |
| <b>Transport</b>  |   |                         |             | U90340                                      | Adenosine kinase  | Adk             | 1.82        |
| NM_031760   | ATP-binding cassette, sub-family B (MDR/TAP), member 11                               | Abcb11                  | 1.54        | NM_017135                                   | Adenylate kinase 3-like 1                                     | Ak3l1           | 1.92        |
| NM_080582   | ATP-binding cassette, sub-family B (MDR/TAP), member 6                                | Abcb6                   | 1.77        | NM_031518                                   | Cd200 antigen   | Cd200           | 0.37        |
| <b>Apoptosis</b>  |   |                         |             | BF565278                                    | DnaJ (Hsp40) homolog, subfamily A, member 4                   | Dnaja4          | 2.01        |
| NM_139258   | Bcl2 modifying factor   | Bmf                     | 1.93        | BF404861                                    | DnaJ (Hsp40) homolog, subfamily C, member 14                  | Dnajc14         | 0.43        |
| NM_019127   | interferon beta 1, fibroblast   | lfnb1                   | 0.51        | AF323608                                    | Fibrinogen-like 2   | Fgl2            | 1.85        |
| BM383722  | NCK-associated protein 1  | Nckap1                  | 2.55        | NM_133286                                   | fibroblast growth factor 8                                    | Fgf8            | 2.38        |
| AI009159  | Tissue inhibitor of metalloproteinase 3 (Sorsby fundus dystrophy, pseudoinflammatory) | Timp3                   | 2.93        | BE107694                                    | G protein-coupled receptor kinase-interactor 2                | Git2            | 1.64        |
| <b>Calcium ion transport</b>                                |   |                         |             | BF404562                                    | Gamma-aminobutyric acid A receptor, gamma 2                   | Gabrg2          | 1.89        |
| AF361341  | Calcium channel, voltage-dependent, gamma subunit 4                                   | Cacng4                  | 1.62        | AF090113                                    | Glutamate receptor interacting protein 2                      | Grip2           | 2.39        |
| AF394940  | Calcium channel, voltage-dependent, L type, alpha 1C subunit                          | Cacna1c                 | 0.66        | BM391206                                    | Histone 1, H2bh   | Hist1h2bh       | 1.59        |
| AF290212  | Calcium channel, voltage-   | Cacna1g                 | 2.3         | X00336                                      | Interferon-alpha 1  | lfna1           | 0.58        |

|                          |   |         |      |           |   |                   |      |
|--------------------------|---|---------|------|-----------|---|-------------------|------|
|                          | dependent, T type, alpha 1G subunit                               |         |      |           |   |                   |      |
| NM_031601                | Calcium channel, voltage-dependent, T type, alpha 1H subunit      | Cacna1h | 1.83 | NM_012983 | Myosin ID   | Myo1d             | 2.91 |
| <b>Cell adhesion</b>     |   |         |      | AI045505  | Myosin X (predicted)                                    | Myo10 predicted   | 0.5  |
| NM_022184                | Calcium/calmodulin-dependent serine protein kinase (MAGUK family) | Cask    | 0.58 | NM_012604 | myosin, heavy polypeptide 3, skeletal muscle, embryonic | Myh3              | 1.87 |
| AF065147                 | CD44 antigen  | Cd44    | 1.54 | NM_013194 | myosin, heavy polypeptide 9, non-muscle                 | Myh9              | 1.58 |
| AI227627                 | CD9 antigen   | Cd9     | 1.6  | AA963282  | Nicotinamide nucleotide adenyltransferase 3             | Nmnat3            | 1.65 |
| NM_031699                | Claudin 1   | Cldn1   | 2.14 | AA955815  | Ribosomal protein S6 kinase, polypeptide 5 (predicted)  | Rps6ka5 predicted |      |
| <b>Blood coagulation</b> |   |         |      | BG671549  | Superoxide dismutase 2, mitochondrial                   | Sod2              | 2.11 |
| NM_022924                | Coagulation factor II   | F2      | 0.49 |           |   |                   |      |
| NM_021698                | Coagulation factor XIII, A1 subunit                               | F13a1   | 2.35 |           |   |                   |      |

---

Figure 2



**Table III:** Validation and evolution of differentially regulated genes by quantitative RT-PCR at -4h, +12h and +36h of the last morphine injection. Data represent fold change in PBMCs of morphine treated rat (n=12-14) as compared to saline treated rats (n=10-12). Statistical analysis was done by Student test \* p<0.05, \*\* p<0.01, \*\*\* p<0.001 as compared to control group.

| Gene                       | -4H       | +12H      | +36H     |
|----------------------------|-----------|-----------|----------|
| Adcy5                      | 1.93*** ↗ | 2* ↗      | 0.39** ↘ |
| Anxa3                      | nd        | 1.88* ↗   | 0.5** ↘  |
| Camk4                      | 1.24* ↗   | 1.38* ↗   | 0.75* ↘  |
| Mir16                      | 1.37** ↗  | 1.39*** ↗ | 0.74* ↘  |
| Rasgrp2                    | 1.16* ↗   | 1.22* ↗   | 1.27* ↗  |
| Itga6                      | 1.84*** ↗ | 1.6** ↗   | 1.81* ↗  |
| Adk                        | 1.58** ↗  | 1.67** ↗  | 1.1 –    |
| Capn2                      | 1.52** ↗  | 1.4* ↗    | 0.98 –   |
| Fgl2                       | 1.95** ↗  | 1.6* ↗    | 1.01 –   |
| Gng11                      | 2.22* ↗   | 2.17** ↗  | 0.98 –   |
| Gprk5                      | 2.43*** ↗ | 1.56* ↗   | 1.01 –   |
| Itgb1                      | 1.69** ↗  | 1.59** ↗  | 0.98 –   |
| Nckap1                     | 2.57* ↗   | 1.69* ↗   | 0.98 –   |
| Rgs10                      | 1.5** ↗   | 1.46** ↗  | 0.97 –   |
| Sod2                       | 2** ↗     | 2.44** ↗  | 1.02 –   |
| Timp3                      | 2.97** ↗  | 2.14** ↗  | 1.09 –   |
| Ap1s1                      | 1.18* ↗   | 1.36* ↗   | 0.97 –   |
| mapk8ip3                   | 1.21 –    | 1.18 –    | 0.64 *↘  |
| Htr2a                      | nd        | 1.38 –    | 0.46** ↘ |
| Ralgps2                    | 1.02 –    | 1.22 –    | 0.29 –   |
| Bmf                        | 0.83 –    | 0.19 –    | nd       |
| Mapk7                      | 1.13 –    | 0.38 –    | nd       |
| Ptpn22 predicted           | 1.08 –    | 1 –       | nd       |
| similar to Mapk5 isoform 2 | 0.97 –    | 0.63 –    | nd       |